CRNO B — Cereno Scientific AB Share News
0.000.00%
Last trade - 00:00- SEK1.50bn
- SEK1.60bn
Brief: Cereno Expands Patent Protection For Epigenetic HDAC Inhibitor CS1:s Second Patent Family
Brief: Cereno Announces Extended Patent Protection In Europe For CS585 Program
Brief: Cereno Announces New Patent Issued In 25 European Countries
Brief: Cereno Warrants Exercised To 99.6%
Brief: Cereno Scientific Announces New Patent Issued In Mexico
Brief: Cereno Appoints Dr. Rahul Agrawal As Chief Medical Officer
Brief: Cereno Scientific Obtains First Patent For Drug Candidate HDAC Inhibitor CS014
Brief: Cereno Scientific Signs Agreement With Cordenpharma
Brief: Cereno Scientific Preclinical Data Conclude Candidate CS585 Provides New Option Of Activating IP Receptor
Brief: Cereno Scientific Obtains First Patent In India For Drug Candidate CS1 Through Its Third Patent Family
Brief: Cereno Expects PAH Study Completion During Q2 2024
Brief: Cereno Scientific Q3 Adj. EPS at SEK -0.05
Brief: Cereno Scientific Secures Loan Of SEK 90 Million
Brief: Cereno Scientific Assists Swedish Economic Crime Authority
Brief: Cereno Scientific Reports Positive Results In Phase II Study Of CS1 In Rare Disease Pulmonary Arterial Hypertension
Brief: Cereno Signs CRO To Conduct Phase I Study Of Drug Candidate CS014
Brief: Cereno Scientific Q2 Result After Financial Items Swings To Profit SEK 10.7 Mln
Brief: Cereno Scientific Q2 Adjusted EPS at SEK -0.05
Brief: Cereno Scientific Appoints Eva Jagenheim As CFO